No Data
No Data
Dian Diagnostics Group (300244.SZ): has cumulatively repurchased 2.07% of shares.
Dian Diagnostics Group (300244.SZ) announced that as of July 2, 2024, the company has repurchased a total of 12,986,200 shares of its own stock through a repurchase special securities account, using the method of concentrated bidding transactions, accounting for 2.07% of the company's current total share capital. The highest fill price was 18.91 yuan/share, the lowest fill price was 11.64 yuan/share, and the total trading amount was RMB 189 million (excluding transaction costs).
Dian Diagnostics Group (300244.SZ) has repurchased a total of 10.3441 million shares, with a total cost of 157 million yuan.
Dian Diagnostics Group (300244.SZ) announced that as of June 30, 2024, the company will trade through centralized bidding...
Tao Jun, Deputy General Manager of Dian Diagnostics Group (300244.SZ), plans to increase shareholding with no less than RMB 1 million.
Dian Diagnostics Group (300244.SZ) announced that Tao Jun, Vice President and Secretary to the Board of Directors, plans to resign from July 2024.
Dian Diagnostics Group (300244.SZ): has repurchased 1.42% of its shares.
Dian Diagnostics Group (300244.SZ) announced on June 24th that as of June 24th, 2024, the company has repurchased 8,884,700 shares of the company's stock through a repurchase dedicated securities account via centralized bidding trading, accounting for 1.42% of the company's total share capital. The highest fill price was 18.91 yuan/share, the lowest fill price was 11.73 yuan/share, and the total transaction amount was 140 million yuan (excluding transaction costs).
Dian Diagnostics Group (300244.SZ): The size of accounts receivable matches the characteristics of the business model and the growth of revenue, mainly from medical institutions and government.
On June 12, Gelonhui reported that Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that the company attaches great importance to the efficiency of accounts receivable collection. The collection of accounts receivable is not only related to the performance and bonuses of employees, but we also established an organizational structure to manage accounts receivables, which decomposes from the group to the subsidiary to the business personnel, establishing a dynamic evaluation and monitoring system. Currently, the size of the company's accounts receivable is matched with the characteristics of the business model and the scale of revenue growth, mainly from medical institutions and the government.
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Is About To Go Ex-Dividend, And It Pays A 0.5% Yield
Dian Diagnostics Group Co.,Ltd. (SZSE:300244) is about to trade ex-dividend in the next three days. The ex-dividend date is one business day before a company's record date, which is the date on which
No Data